Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPESTRY
2023-503312-32-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC) and gastroesophageal junction squamous cell carcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility of bintrafusp alfa with chemoradiotherapy. Planned start Jun 2024; status: authorised.
02
Drugs
bintrafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastroesophageal junction squamous cell carcinoma
Beyond the preview
Go deeper on 2023-503312-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503312-32-00.